

Unilever PLC
Registered in England and Wales
No.41424

Registered office
Port Sunlight, Wirral
Marseyside CH62 4ZD

Unilever PLC
Unilever House
100 Victoria Embankment
London EC4Y 0DY

+44 (0)20 78225252
unilever.com



22nd April 2020

Stock Code: BSE-500696
NSE- HINDUNILVR
ISIN: INE030A01027

BSE Limited
Corporate Relationship Department,
2nd Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051

Sub: Disclosure under Regulation 29(2) of SEBI Takeover Regulation

Dear Sir,

In terms of the requirements of Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation, 2011, please find attached the disclosure of change in percentage of shareholding of Unilever PLC and its affiliates in Hindustan Unilever Limited.

Please note that the change in percentage of shareholding is due to increase in paid up share capital of the Target Company due to allotment of shares to shareholders of GlaxoSmithKline Consumer Healthcare Limited as per the terms of scheme of amalgamation sanctioned by Hon'ble NCLT.

You are requested to take the same on your records.

For Unilever PLC & Affiliates

Richard Hazell,
Authorised Signatory, Unilever PLC

Disclosures under Regulation 29(2) of SEBI
(Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Name of the Target Company (TC)	Hindustan Unilever Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Unilever PLC Brooke Bond Assam Estates Limited Brooke Bond Group Limited Brooke Bond South India Estates Limited Unilever Overseas Holdings A.G. Unilever Overseas Holdings B.V. Unilever UK & CN Holdings Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of the TC are listed	National Stock Exchange Limited BSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share /voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	145,44,12,858	67.19	67.19
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	NIL
e) Total (a+b+c+d)	145,44,12,858	67.19	67.19
Details of acquisition/sale			
a) Shares carrying voting rights	NIL (Refer Note 1)	-5.29	-5.29
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	NIL
e) Total (a+b+c+d)	NIL	NIL	NIL

Note 1: The percentage change in the shareholding of the Promoter and Promoter Group is due to allotment of shares by the Target Company to the shareholders of GlaxoSmithKline Consumer Healthcare Limited, in accordance with the Scheme of Amalgamation sanctioned by Hon'ble NCLT and consequent increase in paid up capital of the Target Company. There is no sale of shares by the Promoter and Promoter Group. The total Promoter and Promoter Group shareholding percentage has been rounded off.

After the acquisition/sale, holding of:			
a) Shares carrying voting rights	145,44,12,858	61.90	61.90
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	NIL
e) Total (a+b+c+d)	145,44,12,858	61.90	61.90
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	N/A #		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	21st April 2020		
Equity share capital / total voting capital of the TC before the said acquisition / sale	216,48,44,187		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	234,94,67,999		
Total diluted share/voting capital of the TC after the said acquisition	234,94,67,999		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of Authorised Signatory:

Place:

Date:

R. C. Herten
LONDON, UK
22nd April 2020